Supplement analysis backed by scientific evidence · PT

← All supplements
Limited evidenceBrain & cognition

DMAE

DMAE (dimethylaminoethanol, deanol) was a prescription drug for childhood behaviour problems until the FDA withdrew it for lack of efficacy in the early 1980s. Its comeback as a nootropic rests on a choline-precursor theory that the pharmacology does not support.

What the science says

  • Raises brain acetylcholine and improves memory Limited evidence

    The premise is that DMAE is methylated to choline and boosts acetylcholine synthesis, but human and animal data show poor conversion in brain tissue and DMAE can actually compete with choline for uptake. Clinical work on DMAE derivatives against scopolamine-induced memory deficits has produced only modest, inconsistent signals, and no adequately powered RCT shows memory or cognitive gains in healthy adults.

  • Helps tardive dyskinesia and movement disorders Limited evidence

    Deanol was studied for antipsychotic-induced tardive dyskinesia through the 1970s-80s. The Cochrane review of cholinergic medication for TD concluded the clinical effects of older cholinergic drugs including deanol remain unclear because trials were too few and too small, and that these drugs currently have little place in routine clinical work.

  • Improves mood, focus and 'mental clarity' Limited evidence

    Deanol was marketed as Deaner for hyperkinetic and learning-disordered children and was removed from the US market in 1983 after the FDA judged the efficacy evidence insufficient. Modern claims rest largely on small EEG studies of DMAE-containing vitamin-mineral combinations, which cannot isolate DMAE's contribution or demonstrate a clinical benefit.

  • Topical DMAE firms skin Limited evidence

    A dermatology review describes a 3% DMAE facial gel improving skin firmness and reducing the appearance of fine lines in controlled use, with the effect attributed to a transient skin-tightening rather than a structural change. Counterbalancing this, in vitro work has reported vacuolisation and reduced viability in cultured fibroblasts at DMAE exposure, so the long-term skin safety picture is unresolved.

Dosage & safety

Studied doseHistorical oral doses were 100-500 mg/day of DMAE bitartrate (Deaner used 25-100 mg/day of deanol acetamidobenzoate in children), typically taken in the morning because it can disrupt sleep. Modern supplements sell 100-350 mg per capsule. Topical products use a 3% DMAE gel applied once daily. No dose has been validated for cognitive benefit in healthy adults.
SafetyCommon effects are headache, insomnia, muscle tension or twitching, vivid dreams and irritability; the stimulating profile is often mistaken for efficacy. DMAE has been reported to precipitate or worsen mania and should be avoided by people with bipolar disorder, and it may aggravate epilepsy. Avoid in pregnancy — related aminoalcohols have raised developmental concerns in animal work and DMAE is untested in human pregnancy. Do not combine with cholinergic medications (donepezil, rivastigmine) or anticholinergics without medical advice. It was withdrawn as a US prescription drug for lack of demonstrated efficacy, which is the single most useful fact about it.

Scientific references

Where to buy

Life Extension, DMAE Bitartrate, 150 mg, 200 Vegetarian Capsules

View on iHerb

Referral link — this site may earn a commission on purchases.

Related in Brain & cognition